AI-Assisted Study Identifies 370 Key Drug Targets for 27 Cancer Types
New Discovery
EPFL Scientists Develop New Class of Oral Peptide Drugs for Complex Diseases
New Study Reveals Evolutionary 'U-turn' in the Fight Against Antibiotic Resistance
How do stem cells decide their fate? A Game-Changer Discovery in Cancer Research
Immune Cell Diversity Could Revolutionize Flu Battle and Vaccine Strategies
High Insulin Levels in Diabetes Increase Risk of Pancreatic Cancer
Innocan Pharma's New Discovery Bolsters cannabidiol Research
Inverse Vaccine Could Treat Multiple Sclerosis and Autoimmune Diseases
Subscribe for the latest news and events
Most Popular
Improving Everolimus Safety in Oncology: Missed Opportunities in Risk Minimization
FDA Approves Wegovy to Reduce Risk of Heart Problems in Obese Adults
Targeting the ‘Don’t Eat Me’ Signal: The Future of Macrophage Checkpoint Inhibitors
A New Era in Liver Disease: FDA Approves First Medication 'Rezdiffra' for NASH
Zongertinib Gains FDA Accelerated Approval for HER2+ NSCLC with 75% ORR
FDA Grants Accelerated Approval to Semaglutide for MASH with Liver Fibrosis
Exploring the Transformative Power of AI in Drug Discovery: A report by S&P Global
EpCAM-Targeting ADC CX-2051 Shows Promising Efficacy in Advanced Colorectal Cancer
NETTER-2 Trial: Lutathera Cuts Risk of Death by 72% in Neuroendocrine Tumor Treatment
NEJM Study Confirms Low-Dose Aspirin Halves Recurrence in Colorectal Cancer
Bayer Poised for Landmark Year with Blockbuster Treatment Advances Across Key Diseases
Transformative One-Time Gene Therapy: FDA Approves Pfizer's BEQVEZ, for Hemophilia B
Pfizer Announces Positive Phase 2b Outcomes for Obesity Drug Candidate, Danuglipron
First-Ever Obstructive Sleep Apnea Drug, Zepbound, Approved by FDA for Obesity
New Horizon in Food Allergy Treatment: FDA Approves Xolair for All Ages
